Natural Alternatives International, Inc. (NAII)

NAII RNA Therapy

BiotechSign Signal Grade

F
Signal Grade
15.5/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
56
Clinical Activity
12
Short Interest
10

Pipeline Overview

Therapeutic Focus
RNA Therapysrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
1 Phase 2
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
11.8 months
Cash Runway Estimate
56/100
Dilution Score
40Warrant Risk
40Convertible Risk
60Offering Ability

Dilution score: 56/100 (HIGH), 11.8 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

0.14%
Float Shorted
1.0
Days to Cover
LOW
Squeeze Risk
-47.8%
SI Change
DECREASING
Trend
6,864
Shares Short

Short interest: 0.14% of float, squeeze risk: LOW

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Natural Alternatives International, Inc..

Full NAII Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.